Literature DB >> 24071009

The association of low serum alanine aminotransferase activity with mortality in the US population.

Constance E Ruhl, James E Everhart.   

Abstract

Elevated alanine aminotransferase (ALT) activity, an important marker of liver injury, has been associated inconsistently with higher mortality. We evaluated whether persons with nonelevated ALT levels are the most appropriate comparison group by examining the relationships of low ALT with mortality and body composition in the US National Health and Nutrition Examination Survey (NHANES). In NHANES 1988-1994, the mortality risk of persons in ALT deciles 1, 2, 3, and 10 was compared with that of persons in deciles 4-9 (mortality was relatively flat across these deciles) over an 18-year period (through 2006) among 14,950 viral-hepatitis-negative adults. In NHANES 1999-2006, low ALT was evaluated in association with dual-energy x-ray absorptiometry body composition measures among 15,028 adults. Multivariate-adjusted mortality was higher for decile 1 (hazard ratio (HR) = 1.42, 95% confidence interval (CI): 1.24, 1.63), decile 2 (HR = 1.27, 95% CI: 1.06, 1.53), and decile 3 (HR = 1.25, 95% CI: 1.04, 1.50) and nonsignificantly higher for decile 10 (HR = 1.21, 95% CI: 0.91, 1.61) than for deciles 4-9. Adjusted appendicular lean mass was decreased among the lowest ALT deciles. In the US population, low ALT was associated with higher mortality risk, possibly attributable to decreased appendicular lean mass. For mortality studies of elevated ALT levels, the most appropriate comparison group is persons in the middle range of ALT rather than all persons with nonelevated ALT.

Entities:  

Keywords:  National Health and Nutrition Examination Survey; alanine aminotransferase; body composition; mortality

Mesh:

Substances:

Year:  2013        PMID: 24071009      PMCID: PMC3858105          DOI: 10.1093/aje/kwt209

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  29 in total

1.  Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery.

Authors:  J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-04       Impact factor: 6.053

2.  Compendium of physical activities: classification of energy costs of human physical activities.

Authors:  B E Ainsworth; W L Haskell; A S Leon; D R Jacobs; H J Montoye; J F Sallis; R S Paffenbarger
Journal:  Med Sci Sports Exerc       Date:  1993-01       Impact factor: 5.411

3.  A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission.

Authors:  J M Guralnik; E M Simonsick; L Ferrucci; R J Glynn; L F Berkman; D G Blazer; P A Scherr; R B Wallace
Journal:  J Gerontol       Date:  1994-03

4.  Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Gastroenterology       Date:  2005-01       Impact factor: 22.682

5.  Body fat and fat-free mass and all-cause mortality.

Authors:  Janne Bigaard; Kirsten Frederiksen; Anne Tjønneland; Birthe Lykke Thomsen; Kim Overvad; Berit Lillienthal Heitmann; Thorkild I A Sørensen
Journal:  Obes Res       Date:  2004-07

Review 6.  Of worms and women: sarcopenia and its role in disability and mortality.

Authors:  Alfred L Fisher
Journal:  J Am Geriatr Soc       Date:  2004-07       Impact factor: 5.562

7.  Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality.

Authors:  V Arndt; H Brenner; D Rothenbacher; B Zschenderlein; E Fraisse; T M Fliedner
Journal:  Int Arch Occup Environ Health       Date:  1998-09       Impact factor: 3.015

8.  Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.

Authors:  Hyeon Chang Kim; Chung Mo Nam; Sun Ha Jee; Kwang Hyub Han; Dae Kyu Oh; Il Suh
Journal:  BMJ       Date:  2004-03-17

9.  Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Gastroenterology       Date:  2003-06       Impact factor: 22.682

Review 10.  Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.

Authors:  Katherine M Flegal; Brian K Kit; Heather Orpana; Barry I Graubard
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

View more
  19 in total

Review 1.  Relevance of autophagy to fatty liver diseases and potential therapeutic applications.

Authors:  Shengmin Yan; Nazmul Huda; Bilon Khambu; Xiao-Ming Yin
Journal:  Amino Acids       Date:  2017-05-06       Impact factor: 3.520

2.  Gallstone disease founded by ultrasonography in functional dyspepsia: prevalence and associated factors.

Authors:  Yaser Froutan; Ahmad Alizadeh; Fariborz Mansour-Ghanaei; Farahnaz Joukar; Hossein Froutan; Faeze Berenji Bagheri; Mohammad Reza Naghipour; Seyed Ali Chavoshi
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity.

Authors:  David Yardeni; Ronen Toledano; Victor Novack; Aryeh Shalev; Arik Wolak; Yaron Rotman; Ohad Etzion
Journal:  J Cardiovasc Pharmacol Ther       Date:  2022 Jan-Dec       Impact factor: 2.457

4.  Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2016-01-22       Impact factor: 17.425

5.  Low Liver Enzymes and Risk of Dementia: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Yifei Lu; James R Pike; Elizabeth Selvin; Thomas Mosley; Priya Palta; A Richey Sharrett; Alvin Thomas; Laura Loehr; A Sidney Barritt; Ron C Hoogeveen; Gerardo Heiss
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.160

6.  Association between alanine aminotransferase and all-cause mortality rate: Findings from a study on Japanese community-dwelling individuals.

Authors:  Ryuichi Kawamoto; Asuka Kikuchi; Taichi Akase; Daisuke Ninomiya; Yoshio Tokumoto; Teru Kumagi
Journal:  J Clin Lab Anal       Date:  2022-04-18       Impact factor: 3.124

7.  High Aspartate Aminotransferase/Alanine Aminotransferase Ratio May Be Associated with All-Cause Mortality in the Elderly: A Retrospective Cohort Study Using Artificial Intelligence and Conventional Analysis.

Authors:  Kei Nakajima; Mariko Yuno; Kazumi Tanaka; Teiji Nakamura
Journal:  Healthcare (Basel)       Date:  2022-04-02

8.  Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up.

Authors:  Miyuki Yokoyama; Tetsu Watanabe; Yoichiro Otaki; Hiroki Takahashi; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Tsuneo Konta; Yoko Shibata; Makoto Daimon; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Dis Markers       Date:  2016-10-31       Impact factor: 3.434

9.  Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression.

Authors:  Tatsuo Yanagawa; Keiko Koyano; Koichiro Azuma
Journal:  Diabetol Int       Date:  2021-01-02

10.  Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank.

Authors:  Ming-Ming He; Zhe Fang; Dong Hang; Feng Wang; Georgios Polychronidis; Liang Wang; Chun-Han Lo; Kai Wang; Rong Zhong; Markus D Knudsen; Scott G Smith; Rui-Hua Xu; Mingyang Song
Journal:  Int J Cancer       Date:  2020-11-02       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.